TuHURA Reports Q3 2026 Results, Advances Clinical Programs

TuHURA reported third-quarter 2026 results, with $1.9 million in cash and cash equivalents at September 30 and $9.2 million in gross proceeds received under its Parkview credit facility. The company highlighted progress in its IFx-2.0 and TBS-2025 programs, including FDA clearance to begin a Phase…